Investors who prefer biotechs with potential platform technologies
that can support multiple drug candidates can still find a lot to like
in Alnylam Pharmaceuticals (NASDAQ:ALNY).
With the shares up about 60% over the past year, a $6.6 billion-plus
market cap, and multiple analysts following the stock, this is no longer
an under-the-radar play on RNA interference, but the company's
preclinical research efforts continue to produce interesting new
candidates while those already in the clinic are showing meaningful
potential.
For a company with one late-stage program, it may seem
hard to argue that Alnylam shares are seriously undervalued today. At
the same time, I would note that trial read-outs later this year and in
2015 could add significant value as investors revise their projected
odds of approval and revenue expectations. I continue to hold these
shares myself and I certainly think they make sense in a portfolio for
investors who are comfortable with the risks that attend biotech stocks.
Read more here:
Alnylam Pharmaceuticals Staying Ridiculously Busy
No comments:
Post a Comment